Modified bloodroot compound shows promise against multidrug-resistant tuberculosis

FHS
October 8, 2024
11:50 pm

A modified compound taken from bloodroot, a wildflower native to North America, effectively fights multidrug-resistant tuberculosis (TB) bacteria in the test tube, according to a new study.

T2D Remission Buffers; Another Sotagliflozin Trial; More Gender-Affirming Care Bans?

People with any evidence of type 2 diabetes remission with diet and lifestyle changes had a 40% lower rate of cardiovascular disease and a 33%

January 24, 2024

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Ivonescimab — a novel first-in-class PD-1/VEGF bispecific antibody — led to clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) as first-line therapy

September 10, 2024

Parental loss at a young age affects a person’s immune system later in life

When a person loses a parent or a caregiver at a young age, their immune system suffers later in life, according to University of Michigan

June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.